$SONX
Sonendo, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023006706 Filed on March 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $10.72M $12.23M $41.66M
YoY Change 18.72% 23.65% 25.48%
Cost Of Revenue $7.378M $8.900M $31.18M
YoY Change 9.24% 19.64% 25.4%
Gross Profit $3.346M $3.330M $10.48M
YoY Change 46.82% 35.81% 25.72%
Gross Profit Margin 31.2% 27.23% 25.16%
Selling, General & Admin $14.67M $14.61M $51.91M
YoY Change 22.37% 29.17% 53.06%
% of Gross Profit 438.31% 438.83% 495.29%
Research & Development $3.494M $3.580M $16.78M
YoY Change -27.96% -15.92% -9.65%
% of Gross Profit 104.42% 107.51% 160.08%
Depreciation & Amortization $339.0K $474.0K $1.052M
YoY Change 37.8% -1.86% -26.23%
% of Gross Profit 10.13% 14.23% 10.04%
Operating Expenses $18.16M $18.09M $68.68M
YoY Change 7.87% 12.94% 30.22%
Operating Profit -$14.81M -$14.76M -$58.20M
YoY Change 1.77% 8.81% 31.07%
Interest Expense -$557.0K -$469.0K -$3.228M
YoY Change -42.34% 20.88% -22.44%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$15.37M -$10.85M -$57.05M
YoY Change -0.97% -20.85% 17.63%
Income Tax $2.000K $2.000K
% Of Pretax Income
Net Earnings -$15.37M -$10.85M -$57.05M
YoY Change -0.97% -20.85% 17.63%
Net Earnings / Revenue -143.33% -88.73% -136.96%
Basic Earnings Per Share -$0.16 -$1.27
Diluted Earnings Per Share -$0.16 -$0.24 -$1.27
COMMON SHARES
Basic Shares Outstanding 50.58M 49.76M 44.93M
Diluted Shares Outstanding 93.39M 44.93M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.95M $91.45M $91.45M
YoY Change 13.46% 8.04% 8.04%
Cash & Equivalents $12.65M $17.67M $17.67M
Short-Term Investments $62.30M $73.78M $73.78M
Other Short-Term Assets $9.091M $8.397M $8.397M
YoY Change 129.11% 136.4% 136.4%
Inventory $15.97M $15.46M $15.46M
Prepaid Expenses
Receivables $6.432M $5.798M $5.798M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $106.4M $121.1M $121.1M
YoY Change 28.46% 22.5% 22.5%
LONG-TERM ASSETS
Property, Plant & Equipment $2.843M $2.860M $5.315M
YoY Change 30.59% 20.88% 3.97%
Goodwill $8.454M $8.454M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $118.0K $118.0K $118.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $17.47M $16.18M $16.18M
YoY Change 9.09% -2.77% -2.77%
TOTAL ASSETS
Total Short-Term Assets $106.4M $121.1M $121.1M
Total Long-Term Assets $17.47M $16.18M $16.18M
Total Assets $123.9M $137.3M $137.3M
YoY Change 25.32% 18.86% 18.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.392M $4.438M $4.438M
YoY Change 141.25% 44.99% 44.99%
Accrued Expenses $4.217M $5.357M $10.09M
YoY Change -4.51% 12.59% 10.74%
Deferred Revenue $582.0K $817.0K
YoY Change -22.09% 5.97%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $34.00K
YoY Change -38.18%
Total Short-Term Liabilities $15.23M $16.72M $16.72M
YoY Change 26.03% 14.09% 14.09%
LONG-TERM LIABILITIES
Long-Term Debt $36.89M $36.75M $36.93M
YoY Change 38.58% 38.69% 39.01%
Other Long-Term Liabilities $735.0K $773.0K $1.685M
YoY Change 42.17% 38.53% -24.03%
Total Long-Term Liabilities $37.63M $37.52M $38.61M
YoY Change 38.65% 38.68% 34.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.23M $16.72M $16.72M
Total Long-Term Liabilities $37.63M $37.52M $38.61M
Total Liabilities $55.33M $55.33M $55.33M
YoY Change 35.95% 27.38% 27.38%
SHAREHOLDERS EQUITY
Retained Earnings -$384.5M -$369.1M
YoY Change 17.37% 18.28%
Common Stock $453.1M $451.1M
YoY Change 17.43% 17.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.58M $81.96M $81.96M
YoY Change
Total Liabilities & Shareholders Equity $123.9M $137.3M $137.3M
YoY Change 25.32% 18.86% 18.86%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$15.37M -$10.85M -$57.05M
YoY Change -0.97% -20.85% 17.63%
Depreciation, Depletion And Amortization $339.0K $474.0K $1.052M
YoY Change 37.8% -1.86% -26.23%
Cash From Operating Activities -$17.00M -$14.25M -$61.10M
YoY Change -46.03% -3.25% 25.72%
INVESTING ACTIVITIES
Capital Expenditures $210.0K $325.0K $1.356M
YoY Change 275.0% -270.16% 112.54%
Acquisitions
YoY Change
Other Investing Activities $12.18M -$36.11M -$73.07M
YoY Change
Cash From Investing Activities $11.97M -$36.43M -$74.43M
YoY Change -21466.07% 18975.39% 3672.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.52M
YoY Change -75.69%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.000K -167.0K 68.53M
YoY Change -98.77% -100.19% -17.93%
NET CHANGE
Cash From Operating Activities -17.00M -14.25M -61.10M
Cash From Investing Activities 11.97M -36.43M -74.43M
Cash From Financing Activities -6.000K -167.0K 68.53M
Net Change In Cash -5.017M -50.85M -66.98M
YoY Change -73.01% -171.72% -303.46%
FREE CASH FLOW
Cash From Operating Activities -$17.00M -$14.25M -$61.10M
Capital Expenditures $210.0K $325.0K $1.356M
Free Cash Flow -$17.21M -$14.57M -$62.46M
YoY Change -45.46% 0.25% 26.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001407973
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40988
CY2022 dei Entity Registrant Name
EntityRegistrantName
Sonendo, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5041718
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
26061 Merit Circle
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Laguna Hills
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92653
CY2022 dei City Area Code
CityAreaCode
949
CY2022 dei Local Phone Number
LocalPhoneNumber
766-3636
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
SONX
CY2022 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
40200000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50583550
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Irvine, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17665000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84641000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
73784000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5798000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2516000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15462000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8150000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8397000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3552000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
121106000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
98859000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2860000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2366000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2455000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2746000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2292000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2956000
CY2022Q4 us-gaap Goodwill
Goodwill
8454000
CY2021Q4 us-gaap Goodwill
Goodwill
8454000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
118000
CY2022Q4 us-gaap Assets
Assets
137285000
CY2021Q4 us-gaap Assets
Assets
115499000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4438000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3061000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5357000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4758000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3616000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3376000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1114000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
975000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2191000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2482000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16716000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14652000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1095000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1730000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
36746000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26496000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
773000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2022Q4 us-gaap Liabilities
Liabilities
55330000
CY2021Q4 us-gaap Liabilities
Liabilities
43436000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49974281
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26383225
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49974281
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26336536
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
451060000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
384132000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-61000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369094000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-312044000
CY2022Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
81955000
CY2021Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
72114000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
51000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
81955000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72063000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137285000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115499000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41656000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33197000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
31176000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24861000
CY2022 us-gaap Gross Profit
GrossProfit
10480000
CY2021 us-gaap Gross Profit
GrossProfit
8336000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51906000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33913000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16776000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18568000
CY2021 sonx Change In Fair Value Of Contingent Earnout
ChangeInFairValueOfContingentEarnout
261000
CY2022 us-gaap Operating Expenses
OperatingExpenses
68682000
CY2021 us-gaap Operating Expenses
OperatingExpenses
52742000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-58202000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-44406000
CY2022 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-3228000
CY2021 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
-4214000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-71000
CY2021 sonx Change In Fair Value Of Forward Obligation
ChangeInFairValueOfForwardObligation
52000
CY2022 sonx Employee Retention Credit Expense
EmployeeRetentionCreditExpense
4382000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57048000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48497000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-57050000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-48499000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57111000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48499000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.52
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.52
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44932952
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44932952
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5694594
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5694594
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-253891000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
281342000
CY2021 sonx Stock Issued During Period Value Settlement Of Outstanding Forward Obligation Into Common Stock On Initial Public Offering
StockIssuedDuringPeriodValueSettlementOfOutstandingForwardObligationIntoCommonStockOnInitialPublicOffering
2698000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9800000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83792000
CY2021 sonx Adjustments To Additional Paid In Capital Reclassification Of Convertible Preferred Stock Warrant Into Common Stock Warrant On Initial Public Offering
AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrantIntoCommonStockWarrantOnInitialPublicOffering
3978000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2372000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-48499000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
72063000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
414000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20516000
CY2022 sonx Adjustments To Additional Paid In Capital Pre Funded Warrant Issued
AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantIssued
38518000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7482000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
73000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-61000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-57050000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
81955000
CY2022 us-gaap Profit Loss
ProfitLoss
-57050000
CY2021 us-gaap Profit Loss
ProfitLoss
-48499000
CY2022 us-gaap Depreciation
Depreciation
1052000
CY2021 us-gaap Depreciation
Depreciation
1426000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
664000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
586000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1100000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
985000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7482000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2372000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-71000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
473000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
778000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
CY2022 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
772000
CY2021 sonx Change In Fair Value Of Forward Obligation
ChangeInFairValueOfForwardObligation
52000
CY2021 sonx Change In Fair Value Of Contingent Earnout
ChangeInFairValueOfContingentEarnout
261000
CY2022 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-70000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3282000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
582000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7414000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3812000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4845000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2646000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1287000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1128000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
17000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-71000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
46000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-72000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
240000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-338000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61072000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48605000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
98723000
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
25650000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1356000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
638000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1335000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74429000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1973000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20516000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
84390000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
38518000
CY2022 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9850000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
414000
CY2022 sonx Payments For Common Stock Initial Public Offering Issuance Costs
PaymentsForCommonStockInitialPublicOfferingIssuanceCosts
598000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
271000
CY2022 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
117000
CY2021 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
667000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
58000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
47000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
450000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68525000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83497000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-66976000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32919000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84641000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51722000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17665000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84641000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
4060000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
3445000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
808000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
424000
CY2022 sonx Lease Liabilities For Operating Lease Right Of Use Assets
LeaseLiabilitiesForOperatingLeaseRightOfUseAssets
-808000
CY2021 sonx Lease Liabilities For Operating Lease Right Of Use Assets
LeaseLiabilitiesForOperatingLeaseRightOfUseAssets
-424000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
281342000
CY2021 sonx Settlement Of Outstanding Forward Obligation Into Common Stock On Initial Public Offering
SettlementOfOutstandingForwardObligationIntoCommonStockOnInitialPublicOffering
2698000
CY2021 sonx Reclassification Of Convertible Preferred Stock Warrant Into Common Stock Warrant On Initial Public Offering
ReclassificationOfConvertiblePreferredStockWarrantIntoCommonStockWarrantOnInitialPublicOffering
3978000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
91400000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-369100000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-57100000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61100000
CY2022 sonx Number Of Operating And Reportable Segments
NumberOfOperatingAndReportableSegments
2
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates, judgements and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes, including estimates of probable losses and expenses, as of the date of the accompanying consolidated financial statements. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Risks</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company has established guidelines to mitigate such potential risks by maintaining the Company’s cash balances with entities that management believes possess high credit quality to limit the amount of credit exposure. Substantially all of the Company’s cash and cash equivalents are maintained at one financial institution domiciled in the United States. Cash and cash equivalents can exceed amounts insured by the Federal Deposit Insurance Corporation of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company has not experienced any losses in its accounts and management believes it is not exposed to any significant credit risk on cash and cash equivalents. The primary objectives of the Company’s investment portfolio are the preservation of capital and maintenance of liquidity.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company believes any concentration of credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and the level of credit worthiness of its customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> individual customer accounted for more than 10% of sales or accounts receivable in 2022 or 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sources materials and services through several vendors. Certain materials are sourced from a single vendor. The loss of certain vendors could result in a temporary disruption of the Company’s commercialization efforts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s products require clearance from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products in development will receive any of these required clearances. The denial or delay of such clearances may have a material adverse impact on the Company’s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business in the future. In addition, after the clearance by the FDA, there is still an ongoing risk of adverse events that did not appear during the device clearance process.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of its products, product liability and the need to obtain additional financing.</span></p>
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9593000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2860000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2366000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q4 sonx Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2022Q4 sonx Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2022Q4 sonx Fair Value Liabilities Level1 To Level2 Transfer Amount
FairValueLiabilitiesLevel1ToLevel2TransferAmount
0
CY2022Q4 sonx Fair Value Liabilities Level2 To Level1 Transfer Amount
FairValueLiabilitiesLevel2ToLevel1TransferAmount
0
CY2022 us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
817000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
771000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
800000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
800000
CY2022 us-gaap Depreciation
Depreciation
1100000
CY2021 us-gaap Depreciation
Depreciation
1400000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41656000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33197000
CY2021Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1620000
CY2020Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1584000
CY2022 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1707000
CY2021 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1515000
CY2022 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1397000
CY2021 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1479000
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1930000
CY2021Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1620000
CY2022Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1340000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1132000
CY2022Q4 us-gaap Standard Product Warranty Accrual Noncurrent
StandardProductWarrantyAccrualNoncurrent
590000
CY2021Q4 us-gaap Standard Product Warranty Accrual Noncurrent
StandardProductWarrantyAccrualNoncurrent
488000
CY2022Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1930000
CY2021Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1620000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 sonx Finite Lived Intangible Asset Weighted Average Amortization Period
FiniteLivedIntangibleAssetWeightedAverageAmortizationPeriod
P7Y7M6D
CY2021 us-gaap Payments To Employees
PaymentsToEmployees
4400000
CY2022 sonx Minimum Amount Tax Benefits Likely Of Being Realized Upon Settlement
MinimumAmountTaxBenefitsLikelyOfBeingRealizedUponSettlement
more than 50%
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9269000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4911000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
427000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
270000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5766000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2969000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15462000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8150000
CY2022Q4 sonx Inventory Reserves For Excess And Obsolete
InventoryReservesForExcessAndObsolete
500000
CY2021Q4 sonx Inventory Reserves For Excess And Obsolete
InventoryReservesForExcessAndObsolete
700000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13477000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11959000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10617000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4715000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2423000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2292000
CY2021 sonx Finite Lived Intangible Asset Weighted Average Amortization Period
FiniteLivedIntangibleAssetWeightedAverageAmortizationPeriod
P7Y7M6D
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4715000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1759000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2956000
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
618000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
442000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
386000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
169000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
677000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2292000
CY2022Q4 sonx Vendor Invoices Current
VendorInvoicesCurrent
2712000
CY2021Q4 sonx Vendor Invoices Current
VendorInvoicesCurrent
2779000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2645000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1979000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5357000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4758000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.98
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
175030
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.44
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
79076
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.39
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
669000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3286
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
34000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
55000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
524000
CY2022Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1340000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
1132000
CY2022Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
817000
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
771000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2191000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2482000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
183000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
70000
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
590000
CY2021Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
488000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
773000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
73784000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
73845000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
331503
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7482000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2372000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7482000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2372000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2000000.0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000000.0
CY2022Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.34
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1000000.0
CY2022Q4 sonx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCostRelatedToVestedOptions
600
CY2022Q4 sonx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost Of Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCostOfFairValue
400
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16102000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2247136
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.13
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1130249
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.73
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3119993
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.59
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2325000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
297516
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.73
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
327720
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.45
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
262222
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.76
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
71199
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.54
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
142000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2756368
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.83
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1510000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1638280
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.75
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
829000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2627362
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.83
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1432000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.16
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6900000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2000000.0
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1114000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1095000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M15D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0887
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1297000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1204000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
120000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
99000
CY2022 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases office space under operating leases with expirations ranging from June 2023 to August 2026, some of which include rent escalations or an option to extend the lease for up to three years per renewal.
CY2022 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2022 us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
the Company has not entered into any leases that have not yet commenced that would entitle the Company to significant rights or create additional obligations.
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1185000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
835000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
377000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
29000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2426000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
217000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2209000
CY2022 us-gaap Lease Cost
LeaseCost
1417000
CY2021 us-gaap Lease Cost
LeaseCost
1303000
CY2022 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1387000
CY2021 us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
1206000
CY2022 us-gaap Lease Cost
LeaseCost
1417000
CY2021 us-gaap Lease Cost
LeaseCost
1303000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
40000000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
40000000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2022 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
2000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
2000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0201
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0331
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0098
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0113
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2041
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2551
CY2022 sonx Effective Income Tax Rate Reconciliation Stock Based Compensation Percent
EffectiveIncomeTaxRateReconciliationStockBasedCompensationPercent
-0.0203
CY2021 sonx Effective Income Tax Rate Reconciliation Stock Based Compensation Percent
EffectiveIncomeTaxRateReconciliationStockBasedCompensationPercent
-0.0020
CY2022 sonx Effective Income Tax Rate Reconciliation Other Deferred Adjustments Percent
EffectiveIncomeTaxRateReconciliationOtherDeferredAdjustmentsPercent
-0.0131
CY2021 sonx Effective Income Tax Rate Reconciliation Other Deferred Adjustments Percent
EffectiveIncomeTaxRateReconciliationOtherDeferredAdjustmentsPercent
0.0056
CY2022 sonx Effective Income Tax Rate Reconciliation Perm Items
EffectiveIncomeTaxRateReconciliationPermItems
-0.0024
CY2021 sonx Effective Income Tax Rate Reconciliation Perm Items
EffectiveIncomeTaxRateReconciliationPermItems
-0.0029
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
78276000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
70731000
CY2022Q4 sonx Deferred Tax Assets Fixed Assets And Intangible Assets
DeferredTaxAssetsFixedAssetsAndIntangibleAssets
1244000
CY2021Q4 sonx Deferred Tax Assets Fixed Assets And Intangible Assets
DeferredTaxAssetsFixedAssetsAndIntangibleAssets
1449000
CY2022Q4 sonx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
514000
CY2021Q4 sonx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
660000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1170000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1178000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
918000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
864000
CY2022Q4 sonx Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
5375000
CY2021Q4 sonx Deferred Tax Assets Tax Credits
DeferredTaxAssetsTaxCredits
4763000
CY2021Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
3000
CY2022Q4 sonx Deferred Tax Assets Employee Retention Credit
DeferredTaxAssetsEmployeeRetentionCredit
172000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3077000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1346000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
890000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
92092000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80538000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
91113000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79476000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
979000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1062000
CY2022Q4 sonx Deferred Tax Liabilities Fixed Assets And Intangible Assets
DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
408000
CY2021Q4 sonx Deferred Tax Liabilities Fixed Assets And Intangible Assets
DeferredTaxLiabilitiesFixedAssetsAndIntangibleAssets
392000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
571000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
670000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
979000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1062000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
91100000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
321600000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
287600000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
186400000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
173400000
CY2022Q4 sonx Deferred Tax Assets Operating Loss Carryforwards Will Not Expired
DeferredTaxAssetsOperatingLossCarryforwardsWillNotExpired
204400000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
3700000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
3300000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4400000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3900000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000.0
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1791000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1575000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
207000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
204000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
22000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
12000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2020000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1791000
CY2022 us-gaap Revenues
Revenues
41656000
CY2021 us-gaap Revenues
Revenues
33197000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
31176000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24861000
CY2022 us-gaap Gross Profit
GrossProfit
10480000
CY2021 us-gaap Gross Profit
GrossProfit
8336000
CY2022 sonx Gross Margin Percentage
GrossMarginPercentage
0.25
CY2021 sonx Gross Margin Percentage
GrossMarginPercentage
0.25
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51906000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33913000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16776000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18568000
CY2021 sonx Change In Fair Value Of Contingent Earnout
ChangeInFairValueOfContingentEarnout
261000
CY2022 us-gaap Operating Expenses
OperatingExpenses
68682000
CY2021 us-gaap Operating Expenses
OperatingExpenses
52742000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-58202000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-44406000
CY2022 us-gaap Depreciation
Depreciation
1052000
CY2021 us-gaap Depreciation
Depreciation
1426000
CY2022Q4 us-gaap Assets
Assets
137285000
CY2021Q4 us-gaap Assets
Assets
115499000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-57050000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-48499000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44932952
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44932952
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5694594
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5694594
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.52
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.52
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5946520
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3789645

Files In Submission

Name View Source Status
0000950170-23-006706-index-headers.html Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
0000950170-23-006706-index.html Edgar Link pending
0000950170-23-006706.txt Edgar Link pending
0000950170-23-006706-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img82560772_0.jpg Edgar Link pending
img82560772_1.jpg Edgar Link pending
img82560772_2.jpg Edgar Link pending
img82560772_3.jpg Edgar Link pending
img82560772_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sonx-20221231.htm Edgar Link pending
sonx-20221231.xsd Edgar Link pending
sonx-ex23_1.htm Edgar Link pending
sonx-ex31_1.htm Edgar Link pending
sonx-ex31_2.htm Edgar Link pending
sonx-ex32_1.htm Edgar Link pending
sonx-ex32_2.htm Edgar Link pending
sonx-20221231_cal.xml Edgar Link unprocessable
sonx-20221231_def.xml Edgar Link unprocessable
sonx-20221231_lab.xml Edgar Link unprocessable
sonx-20221231_pre.xml Edgar Link unprocessable
sonx-20221231_htm.xml Edgar Link completed